Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial

Archives of General Psychiatry

Volumn 57, Issue 10, 2000, Pages 968-976

  Street, Jamie S ^a   Clark, W Scott ^a   Gannon, Kimberley S ^a   Cummings, Jeffrey L ^b   Bymaster, Frank P ^a   Tamura, Roy N ^a   Mitan, Steven J ^a   Kadam, Deborah L ^a   Sanger, Todd M ^a,b   Feldman, Peter D ^a   Tollefson, Gary D ^a   Breier, Alan ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NURSING HOME; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033799993     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.10.968     Document Type: Article

References (53)

1. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease
2. The spectrum of behavioral changes in Alzheimer's disease
3. Assessment of behavioral symptoms in Alzheimer disease
4. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
5. The stage specific temporal course of Alzheimer's disease: Functional and behavioral concomitants based upon cross-sectional and longitudinal observation
6. Overview of depression and psychosis in Alzheimer's disease
7. Longitudinal assessment of symptoms of depression, agitation and psychosis in 181 patients with Alzheimer's disease
8. Psychosis of Alzheimer's disease and related dementias
9. Nursing homeattendants urged to report attacks by residents
10. Resident behavior and staff distress in the nursing home
11. A meta-analysis of controlled trials of neuroleptic treatment in dementia
12. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychoses and disruptive behaviors in Alzheimer's disease
13. Efficacy of olanzapine: An overview of pivotal clinical trials
14. Olanzapine in the treatment of elderly patients with schizophrenia and related disorders
15. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
16. The use of the neuropsychiatric inventory in nursing home residents: Characterization and measurement
17. 'Mini-Mental State': A practical method for grading the cognitive state of patients by the clinician
18. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
19. The impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale
20. Assessing the impact of neuropsychiatric symptoms on distress in professional caregivers
21. The Brief Psychiatric Rating Scale
22. A rating scale for extrapyramidal side effects
23. A rating scale for drug-induced akathisia
24. The application of the principle of intention-to-treat to the analysis of clinical trials
25. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia
26. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial
27. The use of clozapine in older people
28. Clozapine use in female geriatric patients with psychoses
29. Clozapine in older patients with psychosis and behavioral disturbances
30. Clozapine in the elderly
31. Clozapine-induced agranulocytosis: Incidence and risk factors in the United States
32. Quetiapine, a novel antipsychotic Experience in elderly patients with psychotic disorders
33. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease
34. Olanzapine versus placebo in the treatment of acute mania
35. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
36. Pharmacokinetics in the aged: A review
37. Antipyrine metabolism in man: Influence of age, alcohol, caffeine and smoking
38. Drug prescribing for elderly patients
39. Altered pharmacodynamic basis for altered drug action in the elderly
40. Cerebral cortex pathology in aging and Alzheimer disease
41. Aging and drug disposition: Pharmacodynamics
42. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
43. Radioreceptor binding profile of the atypical antipsychotic olanzapine
44. Decreased binding affinity of olanzapine and clozapine for clonal human muscarinic receptor subtypes in intact CHO cells in physiological medium
45. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
46. Review of the preclinical pharmacology of olanzapine: A MARTA class antipsychotic
47. 1-adrenergic receptors in vitro
48. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
49. Extrapyramidal signs, primitive reflexes and frontal lobe function in senile dementia of the Alzheimer type
50. Determinants of spontaneous extrapyramidal symptoms in elderly psychiatric inpatients diagnosed with Alzheimer's disease, major depressive disorders, or psychotic disorders